The factor V Leiden variant, responsible for the phenomenon of activated protein C resistance, was found to be less frequent among British (0.06) and Swedish/Danish (0'15) protein C deficiency patients than previously reported in a Dutch study (0.19). In the Swedish population, a significantly increased frequency ofthe factor V Leiden allele was apparent in protein C deficiency patients as compared to healthy controls. However, this was not found in the British population. Coinheritance of the factor V Leiden variant is therefore unlikely to be the sole determinant of whether a person with protein C deficiency will come to clinical attention. Nevertheless, when patient data were analysed by type of protein C deficiency, it was noted that the frequency of the factor V Leiden variant was 2-8-fold higher in type II patients compared to type I patients. A possible explanation of this disparity is discussed. (J Med Genet 1995;32:543-545) 
V Leiden allele was apparent in protein C deficiency patients as compared to healthy controls. However, this was not found in the British population. Coinheritance of the factor V Leiden variant is therefore unlikely to be the sole determinant of whether a person with protein C deficiency will come to clinical attention. Nevertheless, when patient data were analysed by type of protein C deficiency, it was noted that the frequency of the factor V Leiden variant was 2-8-fold higher in type II patients compared to type I patients. A possible explanation of this disparity is discussed. (J Med Genet 1995; 32:543-545) A high prevalence of the newly discovered factor V (FV) Leiden variant (Arg506-+Gln),' responsible for the phenomenon of activated protein C (APC) resistance,2-6 has been recently reported in subjects with clinically symptomatic protein C deficiency.7 Coinheritance of this frequent variant with a protein C gene lesion could therefore explain the difference in thrombotic risk noted between families with clinically symptomatic (overt) protein C deficiency and those with the much more common clinically asymptomatic (covert) deficiency state.89 In order to examine this postulate, we have determined the prevalence of the FV Leiden variant among unrelated protein C deficient patients of different ethnic/ 4 The extent of association between the FV Leiden allele and protein C deficiency thus appears contentious. On one hand, the frequency of the variant in British protein C deficient patients is only slightly higher than in controls from the same population (Fisher's p = 020) and the relative risk" for protein C deficiency conferred by heterozygous or homozygous carriership of the FV Leiden allele is 1 8. In Swedish protein C deficient patients, however, the frequency of the FV Leiden allele is significantly higher than noted in healthy controls from the same population4 (p = 0-0001, by reference to the underlying Bernouilli distribution), and a relative risk of 4d1, conferred by heterozygous or homozygous carriership of the FV Leiden allele, results when a Hardy-Weinberg equilibrium frequency of healthy non-carriers is assumed.
In summary, we conclude that the prevalence of the FV Leiden variant among patients with symptomatic protein C deficiency may not be consistently as high as previously suggested7
and that geographical differences in the pattern of coinheritance of the two traits may exist. Nevertheless, the higher relative risk for protein C deficiency conferred by homozygosity for the FV Leiden variant (table 1, British patients), although subject to considerable sampling variance, suggests that protein C deficient subjects who are homozygous for the FV Leiden variant are more likely to come to clinical attention than those who are heterozygous.
Two points are, however, worthy of further mention. Firstly, the relative importance of specific protein C defects could not be properly assessed without the comprehensive characterisation of all the mutations segregating in the 120 families. This rather laborious programme is under way but still incomplete. This notwithstanding, there is currently no evidence for protein C gene lesions differing in their likelihood of coming to clinical attention.'2'-4 Moreover, a recent study has revealed that founder effects are of relatively minor importance for the geographical distribution of known protein C gene lesions in European populations.'4 On the whole, therefore, geographical differences in the protein C mutational spectrum are unlikely to represent a major contributory factor to the observed population differences in the frequency of the factor V Leiden variant.
ANALYSIS BY TYPE OF PROTEIN C DEFICIENCY
When the total patient data, including those of diverse ethnic/geographical origin ("Others" in table 1), were analysed by type of protein C deficiency, it was noted that the frequency of the FV Leiden variant was 2-8-fold higher in type II patients than in type I patients (table  2) . Although the significance ofthis observation was borderline (Fisher's p=0 089), and thus awaits confirmation by further studies, we offer the following possible explanation.
Together with protein S and factor V, APC forms a 1:1:1 stoichiometric complex on the phospholipid surface that is capable of inactivating factor VIIIa. 5 The FV Leiden defect is likely to reduce the level of this inactivating complex. This is because thrombin generation is increased in APC resistant plasma owing to the excess of factor Va."' Factor V activated by thrombin is, however, inefficient as a cofactor in the inactivation of factor VIIIa.'5 Although the reduced synthesis of protein C, characteristic of type I protein C deficiency state, would presumably reduce the level of factor VIIIa inactivating complex still further, a normal level offactor V is still available to wild type protein C molecules for complex formation. By contrast, a dysfunctional (type II) protein C molecule might still be able to interact with protein S and factor V to generate a nonfunctional complex. Once formed, this inactive complex could sequester factor V and protein S thereby reducing the amount of factor V accessible to wild type protein C (it might also compete with its functional counterpart for access to factor VIIIa). This reduction might explain why carriership of the FV Leiden variant increases the likelihood of clinical detection more dramatically for type II protein C deficiency than for type I deficiency patients.
